Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis by Ivo Veletic, Sanja Prijic, Taghi Manshouri, Graciela M. Nogueras-Gonzalez, Srdan Verstovsek, Zeev Estrov

Get full text

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes by Taghi Manshouri, Ivo Veletic, Ping Li, C. Cameron Yin, Sean M. Post, Srdan Verstovsek, Zeev Estrov

Get full text

Therapy-related myelofibrosis does not appear to exist by Lucia Masarova, Gabriele Todisco, Taghi Manshouri, Kate J. Newberry, Jorge E. Cortes, Hagop M. Kantarjian, Zeev Estrov, Srdan Verstovsek

Get full text

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis by Uri Rozovski, Srdan Verstovsek, Taghi Manshouri, Vilma Dembitz, Ksenija Bozinovic, Kate Newberry, Ying Zhang, Joseph E. Bove, Sherry Pierce, Hagop Kantarjian, Zeev Estrov

Get full text

P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS. by Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Mackenzie Dobbins, Nitin Jain, Hussein Abbas, Steven Kornblau, Abhishek Maiti, Ivo Veletic, Taghi Manshouri, Sharon Bledsoe, Mary Ann Richie, Nakiuda Hall-Moore, Lingsha Zhou, Xuemei Wang, Hagop Kantarjian, Zeev Estrov, Srdan Verstovsek

Get full text

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial by Srdan Verstovsek, Lynda Foltz, Vikas Gupta, Robert Hasserjian, Taghi Manshouri, John Mascarenhas, Ruben Mesa, Olga Pozdnyakova, Ellen Ritchie, Ivo Veletic, Katia Gamel, Habib Hamidi, Lyrialle Han, Brian Higgins, Kerstin Trunzer, Marianne Uguen, Dao Wang, Tarec Christoffer El-Galaly, Boyan Todorov, Jason Gotlib

Get full text